News
On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is ...
Goldman Sachs analysts began coverage of Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $24, on June 6.
Fifty-five attorneys general around the country have now signed on to a $7.4 billion settlement with drugmaker Purdue Pharma and its owners, the Sackler family, over the opioid crisis, officials said.
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established ...
Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established ...
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology ...
The strategic partnership presents a significant step forward in the global development of TEV-56278, giving Teva the opportunity to leverage Fosun Pharma-generated data in other geographies.
In 2020, we committed to launching eight Access to Medicines programs by 2025, aimed at providing treatments to underserved populations worldwide via customized, localized models conducted with ...
As a sales rep for drug manufacturers Questcor, Lisa Pratta always suspected the company’s business practices weren’t just immoral but illegal, too, as she explains in “False Claims — One ...
Here are 10 new shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists. Editor’s note: The drugs listed are in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results